Literature DB >> 29849794

Tetrandrine suppresses lung cancer growth and induces apoptosis, potentially via the VEGF/HIF-1α/ICAM-1 signaling pathway.

Zhuo Chen1, Liang Zhao2, Feng Zhao1, Guanghai Yang1, Jian Jun Wang1.   

Abstract

The present study investigated the effect of tetrandrine on lung cancer cell growth and apoptosis, and its possible underlying molecular mechanism. A549 human lung cancer cells were incubated with between 2.5 and 10 µM tetrandrine for 12, 24 and 48 h, following which the effect of tetrandrine on cell viability and apoptosis were assessed using an MTT assay and flow cytometry. ELISA and western blotting were used to analyze VEGF activity, and the expression of poly (ADP-ribose) polymerase (PARP), phosphorylated protein kinase B (Akt), Bcl-2-associated X protein (Bax), hypoxia inducible factor (HIF)-1α and inter-cellular adhesion molecule-1 (ICAM-1). Tetrandrine effectively suppressed the growth of and induced apoptosis in A549 lung cancer cells. The expression of PARP, Bax, intercellular adhesion molecule-1 (ICAM-1) and vascular endothelial growth factor (VEGF) was significantly upregulated, and the phosphorylation of Akt and expression of HIF-1α was significantly suppressed in A549 lung cancer cells. Therefore, tetrandrine may suppress cell viability and induce apoptosis via the VEGF/HIF-1α/ICAM-1 signaling pathway.

Entities:  

Keywords:  hypoxia-inducible factor-1α; intercellular adhesion molecule-1; lung cancer; tetrandrine; vascular endothelial growth factor

Year:  2018        PMID: 29849794      PMCID: PMC5962877          DOI: 10.3892/ol.2018.8190

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  24 in total

1.  Influence of erbanxiao solution on inhibiting angiogenesis in stasis toxin stagnation of non-small cell lung cancer.

Authors:  Junbao Liu; Yanqing Liu
Journal:  J Tradit Chin Med       Date:  2013-06       Impact factor: 0.848

2.  Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer.

Authors:  Xichun Hu; Jian Zhang; Binghe Xu; Zefei Jiang; Joseph Ragaz; Zhongsheng Tong; Qingyuan Zhang; Xiaojia Wang; Jifeng Feng; Danmei Pang; Minhao Fan; Jin Li; Biyun Wang; Zhonghua Wang; Qunling Zhang; Si Sun; Chunmei Liao
Journal:  Int J Cancer       Date:  2014-03-20       Impact factor: 7.396

3.  Important prognostic factors for the long-term survival in non-small cell lung cancer patients treated with combination of chemotherapy and conformal radiotherapy.

Authors:  Simonida Crvenkova; Meri Pesevska
Journal:  J BUON       Date:  2015 May-Jun       Impact factor: 2.533

4.  Immunoreactivity of ICAM-1 in human tumors, metastases and normal tissues.

Authors:  Sarah H Hayes; Gail M Seigel
Journal:  Int J Clin Exp Pathol       Date:  2009-06-10

5.  The single nucleotide polymorphism g.1548A >G (K469E) of the ICAM-1 gene is associated with worse prognosis in non-small cell lung cancer.

Authors:  Eirini Thanopoulou; George Kotzamanis; Ioannis S Pateras; Nicholaos Ziras; Alexandros Papalambros; Theodoros Mariolis-Sapsakos; Fragiska Sigala; Elizabeth Johnson; Athanassios Kotsinas; Andreas Scorilas; Vassilis G Gorgoulis
Journal:  Tumour Biol       Date:  2012-05-06

6.  Erlotinib-cisplatin combination inhibits growth and angiogenesis through c-MYC and HIF-1α in EGFR-mutated lung cancer in vitro and in vivo.

Authors:  Jasmine G Lee; Reen Wu
Journal:  Neoplasia       Date:  2015-02       Impact factor: 5.715

7.  A randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, non-small cell lung cancer.

Authors:  Nabil Mubarak; Rabab Gaafar; Samir Shehata; Tarek Hashem; Dani Abigeres; Hamdy A Azim; Gamal El-Husseiny; Hamed Al-Husaini; Zhixin Liu
Journal:  BMC Cancer       Date:  2012-09-24       Impact factor: 4.430

8.  A modified Phase I trial of radiation dose escalation in 3D conformal radiation therapy with concurrent vinorelbine and carboplatin chemotherapy for non-small-cell lung cancer.

Authors:  Qiang Lin; Yue'e Liu; Na Wang; Yuehua Huang; Xiaohui Ge; Xiaocang Ren; Xueji Chen; Jing Hu; Zhijun Guo; Yannan Zhao; Junichi Asaumi
Journal:  J Radiat Res       Date:  2012-09-17       Impact factor: 2.724

Review 9.  The cellular response to vascular endothelial growth factors requires co-ordinated signal transduction, trafficking and proteolysis.

Authors:  Gina A Smith; Gareth W Fearnley; Darren C Tomlinson; Michael A Harrison; Sreenivasan Ponnambalam
Journal:  Biosci Rep       Date:  2015-08-18       Impact factor: 3.840

10.  microRNA targeting of the P2X7 purinoceptor opposes a contralateral epileptogenic focus in the hippocampus.

Authors:  Eva M Jimenez-Mateos; Marina Arribas-Blazquez; Amaya Sanz-Rodriguez; Caoimhin Concannon; Luis A Olivos-Ore; Cristina R Reschke; Claire M Mooney; Catherine Mooney; Eleonora Lugara; James Morgan; Elena Langa; Alba Jimenez-Pacheco; Luiz Fernando Almeida Silva; Guillaume Mesuret; Detlev Boison; M Teresa Miras-Portugal; Michael Letavic; Antonio R Artalejo; Anindya Bhattacharya; Miguel Diaz-Hernandez; David C Henshall; Tobias Engel
Journal:  Sci Rep       Date:  2015-12-03       Impact factor: 4.379

View more
  12 in total

Review 1.  Natural Products in Preventing Tumor Drug Resistance and Related Signaling Pathways.

Authors:  Chuansheng Yang; Zhikai Mai; Can Liu; Shuanghong Yin; Yantao Cai; Chenglai Xia
Journal:  Molecules       Date:  2022-05-30       Impact factor: 4.927

2.  Plant Alkaloid Tetrandrine Is a Nuclear Receptor 4A1 Antagonist and Inhibits Panc-1 Cell Growth In Vitro and In Vivo.

Authors:  Hyo-Seon Lee; Dae Hwan Kim; In-Seon Lee; Ji-Hyun Park; Gregory Martin; Stephen Safe; Keuk-Jun Kim; Joung-Hee Kim; Byung Ik Jang; Syng-Ook Lee
Journal:  Int J Mol Sci       Date:  2022-05-09       Impact factor: 6.208

3.  Anticancer Activity of Tetrandrine by Inducing Apoptosis in Human Breast Cancer Cell Line MDA-MB-231 In Vivo.

Authors:  Chun-Hui Wang; Jia-Min Yang; Yu-Bo Guo; Jing Shen; Xiao-Hua Pei
Journal:  Evid Based Complement Alternat Med       Date:  2020-06-30       Impact factor: 2.629

4.  Tetrandrine Reverses Paclitaxel Resistance in Human Ovarian Cancer via Inducing Apoptosis, Cell Cycle Arrest Through β-Catenin Pathway.

Authors:  Luo Jiang; Rui Hou
Journal:  Onco Targets Ther       Date:  2020-04-30       Impact factor: 4.147

5.  Clinical efficacy of acetylcysteine combined with tetrandrine tablets in the treatment of silicosis and the effect on serum IL-6 and TNF-α.

Authors:  Jianling Sun; Pingping Song; Yan Wang; Yanxia Chen
Journal:  Exp Ther Med       Date:  2019-08-30       Impact factor: 2.447

6.  Tetrandrine Ameliorates Myocardial Ischemia Reperfusion Injury through miR-202-5p/TRPV2.

Authors:  Wei Zhao; Youyang Wu; Fanhao Ye; Shiwei Huang; Hao Chen; Rui Zhou; Wenbing Jiang
Journal:  Biomed Res Int       Date:  2021-03-08       Impact factor: 3.411

Review 7.  The crosstalk between HIFs and mitochondrial dysfunctions in cancer development.

Authors:  Xingting Bao; Jinhua Zhang; Guomin Huang; Junfang Yan; Caipeng Xu; Zhihui Dou; Chao Sun; Hong Zhang
Journal:  Cell Death Dis       Date:  2021-02-26       Impact factor: 8.469

8.  A 4-gene-based hypoxia signature is associated with tumor immune microenvironment and predicts the prognosis of pancreatic cancer patients.

Authors:  Jianfeng Ding; Xiaobo He; Xiao Cheng; Guodong Cao; Bo Chen; Sihan Chen; Maoming Xiong
Journal:  World J Surg Oncol       Date:  2021-04-17       Impact factor: 2.754

9.  Study on the molecular mechanisms of tetrandrine against pulmonary fibrosis based on network pharmacology, molecular docking and experimental verification.

Authors:  Jie Li; Yi Wang; Rui Wang; Meng-Yu Wu; Jing Shan; Ying-Chi Zhang; Hai-Ming Xu
Journal:  Heliyon       Date:  2022-08-13

10.  Network Pharmacology Approach Reveals the Potential Immune Function Activation and Tumor Cell Apoptosis Promotion of Xia Qi Decoction in Lung Cancer.

Authors:  Song Zhang; Yun Wang
Journal:  Med Sci (Basel)       Date:  2019-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.